SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Bharat Parenterals - Quaterly Results

31 Jan 2026 Evaluate
The sales is pegged at Rs. 414.13 millions for the December 2025 quarter. The mentioned figure indicates a decline of about -38.50% as against Rs. 673.40 millions during the year-ago period.A big decline of -70.57% was reported for the quarter ended December 2025 to Rs. 19.14  millions from Rs. 65.03 millions of corresponding previous quarter.Operating Profit reported a sharp decline to 57.47 millions from 121.40 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202512 202412 % Var 202512 202412 % Var 202503 202403 % Var
Sales 414.13 673.40 -38.50 1774.83 2238.50 -20.71 3041.30 2579.80 17.89
Other Income 22.76 37.90 -39.95 81.06 122.90 -34.04 145.50 80.40 80.97
PBIDT 57.47 121.40 -52.66 291.77 412.80 -29.32 481.50 410.00 17.44
Interest 5.48 14.10 -61.13 29.28 33.10 -11.54 47.90 38.00 26.05
PBDT 51.99 107.30 -51.55 262.49 379.70 -30.87 433.60 372.00 16.56
Depreciation 21.03 18.60 13.06 63.33 52.20 21.32 70.50 64.00 10.16
PBT 30.96 88.70 -65.10 199.16 327.50 -39.19 363.10 308.00 17.89
TAX 11.82 23.67 -50.06 52.72 85.77 -38.53 98.60 82.10 20.10
Deferred Tax 0.62 -1.46 -142.47 -6.88 -6.56 4.88 -7.20 -4.50 60.00
PAT 19.14 65.03 -70.57 146.44 241.73 -39.42 264.50 225.90 17.09
Equity 68.92 68.92 0.00 68.92 68.92 0.00 68.90 58.20 18.38
PBIDTM(%) 13.88 18.03 -23.02 16.44 18.44 -10.85 15.83 15.89 -0.38

Bharat Parenterals Share Price

1213.10 32.30 (2.74%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×